Expression of the PDE5 enzyme on human retinal tissue: New aspects of PDE5 inhibitors ocular side effects

Eye

Volumn 22, Issue 1, 2008, Pages 144-149

  Foresta, C ^a   Caretta, N ^a   Zuccarello, D ^a   Poletti, A ^b   Biagioli, A ^a   Caretti, L ^c   Galan, A ^c  

^a UNIVERSITY OF PADOVA   (Italy)

^b S Bassano Hospital   (Italy)

^c S ANTONIO HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

PHOSPHODIESTERASE; PHOSPHODIESTERASE 6; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; SILDENAFIL; TADALAFIL; UNCLASSIFIED DRUG;

ADULT; ARTERY BLOOD FLOW; ARTICLE; BLOOD FLOW VELOCITY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; COLOR ULTRASOUND FLOWMETRY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS CAVERNOSUM; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DOUBLE BLIND PROCEDURE; ENDOTHELIUM CELL; ENZYME LOCALIZATION; EYE DISEASE; FLUSHING; HEADACHE; HEART RATE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MEDICAL RESEARCH; NORMAL HUMAN; NOSE CONGESTION; OPHTHALMIC ARTERY; PHOTORECEPTOR; PHOTOSENSITIVITY; PROTEIN EXPRESSION; RETINA; RETINA BIPOLAR GANGLION CELL; RETINA BLOOD VESSEL; RETINA CONE; RETINA GANGLION CELL; RETINA ROD; SIDE EFFECT; SINGLE DRUG DOSE; SKIN; SMOOTH MUSCLE FIBER; SPERM; SYSTOLIC BLOOD PRESSURE; TESTIS; TIME; VOLUNTEER; WESTERN BLOTTING;

EID: 38349173402     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/sj.eye.6702908     Document Type: Article

References (46)

1. Wright PJ. Comparison of phosphodiesterase type 5 (PDE5) inhibitors. Int J Clin Pract 2006; 60: 967-975.
2. Cirino G, Fusco F, Imbimbo C, Mirone V. Pharmacology of erectile dysfunction in man. Pharmacol Ther 2006; 111: 400-423.
3. Burnett AL. Phosphodiesterase 5 mechanisms and therapeutic applications. Am J Cardiol 2005; 96(12B): 29M-31M.
4. Seftel AD. Phosphodiesterase type 5 inhibitors: Molecular pharmacology and interactions with other phosphodiesterases. Curr Pharm Des 2005; 11, 4047-4058.
5. Laties A, Sharlip I. Ocular safety in patients using sildenafil citrate therapy for erectile dysfunction. J Sex Med 2006; 3: 12-27.
6. Sponsel WE, Paris G, Sandoval SS, Sanford DK, Harrison JM, Elliott WR et al. Sildenafil and ocular perfusion, N Engl J Med 2000; 342: 1680.
7. Dundar SO, Dundar M, Kocak I, Dayanir Y, Ozkan SB. Effect of sildenafil on ocular haemodynamics. Eye 2001; 15: 507-510.
8. Paris G, Sponsel WE, Sandoval SS, Elliott WR, Trigo Y, Sanford DK et al. Sildenafil increases ocular perfusion. Int Ophthalmol 2001; 23: 355-358.
9. Ignarro LJ, Cirino G, Casini A, Napoli CJ. Nitric oxide as a signaling molecule in the vascular system: An overview. Cardiovasc Pharmacol 1999; 34: 879-886.
10. Goldstein I, Lue TF, Padma-Nathan H, Rosen RC, Steers WD, Wicker PA. Oral Sildenafil in the treatment of erectile dysfunction. N Engl J Med 1998; 338: 1397-1404.
11. Schwarz ER, Kapur V, Rodriguez J, Rastogi S, Rosanio S. The effects of chronic phosphodiesterase-5 inhibitor use on different organ systems. Int J Impot Res 2007; 12: 381-391.
12. Waldkirch E, Uckert S, Yildirim H, Sohn M, Jonas U, Stief CG et al Cyclic AMP-specific and cyclic GMP-specific phosphodiesterase isoenzymes in human cavernous arteries - immunohistochemical distribution and functional significance. World J Urol 2005; 23 405-410.
13. Lin CS. Tissue expression, distribution, and regulation of PDE5. Int J Impot Res 2004; 16: S8-S10.
14. Jackson G. Hemodynamic and exercise effects of phosphodiesterase 5 inhibitors. Am J Cardiol 2005; 96: 32M-36M.
15. Rashid A. The efficacy and safety of PDE5 inhibitors. Clin Cornerstone 2005; 7: 47-56.
16. Kim BJ, Rhee PL, Son HJ. Sildenafil prescribed for erectile dysfunction may induce esophageal symptoms. J Clin Gastroenterol 2005; 39 643-644.
17. Chabre M, Deterre P. Molecular mechanism of visual transduction. Eur J Biochem 1989; 179: 255-266.
18. Arshavsky VY, Lamb TD, Pugh Jr EN. G proteins and phototransduction. Annu Rev Physiol 2002; 64: 153-187.
19. Yamazaki A, Moskvin O, Yamazaki RK. Phosphorylation by cyclin-dependent protein kinase 5 of the regulatory subunit (Pgamma) of retinal cgmp phosphodiesterase (PDE6): Its implications in phototransduction. Adv Exp Med Biol 2002; 514: 131-153.
20. Gonzalez CM, Bervig T, Podlasek C, Huang CF, McKenna KE, McVary KT. Sildenafil causes a dose-and time-dependent downregulation of phosphodiesterase type 6 expression in the rat retina. Int J Impot Res 1999; 11(Suppl 1): S9-S14.
21. Marmor MF, Kessler R. Sildenafil (Viagra) and ophthalmology. Surv Ophthalmol 1999; 44: 153-162.
22. Vobig MA, Klotz T, Staak M, Bartz-Schmidt KU, Engelmann U, Walter P. Retinal side effects of sildenafil. Lancet 1999; 353(9150): 375.
23. Vobig M.A. Retinal side effects of sildenafil. Lancet 1999; 353 9162): 1442.
24. Cote RH. Characteristics of photoreceptor PDE (PDE6): Similarities and differences to PDE5. Int J Impot Res 2004; 16(Suppl 1): S28-S33.
25. Jagle H, Jagle C, Serey L, Yu A, Rilk A, Sadowski B et al. Visual short-term effects of Viagra: Double-blind study in healthy young subjects. Am J Ophthalmol 2004; 137: 842-849.
26. Stockman A, Sharpe LT, Tufail A, Kell PD, Jeffery G. Viagra slows the visual response to flicker. Curr Biol 2006; 24: R44-R45.
27. Sponsel WE, Paris G, Sandoval SS, Sanford DK, Harrison JM, Elliott WR et al. Sildenafil and ocular perfusion. N Engl J Med 2000; 342: 1680.
28. Dundar SO, Dundar M, Kocak I, Dayanir Y, Ozkan SB. Effect of sildenafil on ocular haemodynamics. Eye 2001; 15: 507-510.
29. Paris G, Sponsel WE, Sandoval SS, Elliott WR, Trigo Y, Sanford DK et al. Sildenafil increases ocular perfusion. Int Ophthalmol 2001; 23: 355-358.
30. Koksal M, Ozdemir H, Kargi S, Yesilli C, Tomac S, Mahmutyazicioglu K et al. effects of sildenafil on ocular blood flow. Acta Ophthalmol Scand 2005; 83: 355-359.
31. Kurtulan E, Gulcu A, Secil M, Celebi I, Aslan G, Esen AA. Effects of sildenafil on ocular perfusion demonstrated by color Doppler ultrasonography. Int J Impot Res 2004; 16: 244-248.
32. Grunwald JE, Siu KK, Jacob SS, Dupont J. Effect of sildenafil citrate (Viagra) on the ocular circulation. Am J Ophthalmol 2001; 131 751-755.
33. Muradov H, Boyd KK, Artemyev NO. Analysis of PDE6 function using chimeric PDE5/6 catalytic domains. Vision Res 2006, 46: 860-868.
34. Zhang X, Cote RH. cGMP signalling in vertebrate retinal photoreceptor cells. Front Biosci 2005; 10: 1191-1204.
35. Granovsky AE, Artemyev NO. Partial reconstitution of photoreceptor cGMP phosphodiesterase characteristics in cGMP phosphodiesterase-5. J Biol Chem 2001; 276: 21698-21703.
36. Stacey P, Rulten S, Dapling A, Phillips SC. Molecular cloning and expression of human cGMPbinding cGMP-specific phosphodiesterase (PDE5). Biochem Biophys Res Commun 1998; 247: 249-254.
37. Metelitsina TI, Grunwald JE, DuPont JC, Ying GS. Effect of Viagra on the foveolar choroidal circulation of AMD patients. Exp Eye Res 2005; 81: 159-164.
38. Vatansever HS, Kayikciouglu O, Gumus B. Histopathologic effect of chronic use of sildenafil citrate on the choroids & retina in male rats. Indian J Med Res 2003; 117: 211-215.
39. McCulley TJ, Luu JK, Marmor MF, Feuer WJ. Effects of sildenafil citrate (Viagra) on choroidal congestion. Ophthalmologica 2002; 216: 455-458.
40. Neves G, Lagnado L. The retina. Curr Biol 1999; 9: R674-R677.
41. Trexler EB, Li W, Massey SC. Simultaneous contribution of two rod pathways to All amacrine and cone bipolar cell light responses. J Neurophysiol 2005; 93: 1476-1485.
42. Dacey DM, Liao HW, Peterson BB, Robinson FR, Smith VC, Pokorny J et al. Melanopsin-expressing ganglion cells in primate retina signal colour and irradiance and project to the LGN. Nature 2005; 17 749-754.
43. Nirenberg S, Carcieri SM, Jacobs AL, Lathman PE. Retinal ganglion cells act largely as independent encoders. Nature 2001; 411: 698-701.
44. Pache M, Meyer P, Prunte C, Orgul S, Nuttli I, Flammer J. Sildenafil induces retinal vasodilation in healthy subjects. Br J Ophthalmol 2002; 86: 156-158.
45. Toda N, Nakanishi-Toda M. Nitric oxide: Ocular blood flow, glaucoma, and diabetic retinopathy. Prog Retin Eye Res 2007; 26: 205-238.
46. Goldstein IM, Ostwald P, Roth S. Nitric oxide: A review of its role in retinal function and disease. Vision Res 1996; 36: 2979-2994.